Sorrento Therapeutics, Inc. (67)

Browse by Contract Category

Contracts

Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan, as amended (Filed With SEC on December 16, 2022)
Bridge Loan Agreement, dated as of September 30, 2022, by and between Sorrento Therapeutics, Inc. and B. Riley Commercial Capital, LLC (Filed With SEC on November 8, 2022)
Amendment No. 1 to Sponsor Support Agreement, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and each of the Persons set forth on... (Filed With SEC on September 14, 2022)
Amendment No. 1 to Agreement and Plan of Merger, dated as of September 12, 2022, by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc. and Scilex Holding Company (Filed With SEC on September 14, 2022)
Amendment No. 1 to Amended and Restated Sales Agreement, dated as of December 23, 2021, by and among Sorrento Therapeutics, Inc., Cantor Fitzgerald & Co., B. Riley Securities,... (Filed With SEC on December 23, 2021)
Exclusive License Agreement, dated as of March 4, 2021, by and between Sorrento Therapeutics, Inc. and the Icahn School of Medicine at Mount Sinai (Filed With SEC on May 5, 2021)
Lease Agreement, dated November 13, 2018, between Sorrento Therapeutics, Inc. and HCP Life Science Estates, Inc (Filed With SEC on March 15, 2019)
Stockholder Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc. and Vickers Vantage Corp. I (Filed With SEC on September 14, 2022)
Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex... (Filed With SEC on September 14, 2022)
Consent Under and Amendment No. 4 to Indenture, dated June 3, 2022, by and among Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., U.S. Bank Trust Company, National... (Filed With SEC on June 3, 2022)
Offer Letter, dated April 27, 2022, between Scilex Holding Company and Elizabeth A. Czerepak (Filed With SEC on April 28, 2022)
Offer Letter, dated April 27, 2022, between Sorrento Therapeutics, Inc. and Elizabeth A. Czerepak (Filed With SEC on April 28, 2022)
Form of Amended and Restated Registration Rights Agreement (Filed With SEC on March 18, 2022)
Company Stockholder Support Agreement, dated as of March 17, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Vickers Vantage Corp. I (Filed With SEC on March 18, 2022)
Sponsor Support Agreement, dated as of March 17, 2022, by and among Vickers Vantage Corp. I and each of the Persons set forth on Schedule I attached thereto (Filed With SEC on March 18, 2022)
Agreement and Plan of Merger, dated as of March 17, 2022, by and among Vickers Vantage Corp. I, Vantage Merger Sub Inc. and Scilex Holding Company (Filed With SEC on March 18, 2022)
Description of Securities of Sorrento Therapeutics, Inc (Filed With SEC on March 11, 2022)
Agreement and Plan of Merger, dated January 14, 2022, by and among Sorrento Therapeutics, Inc., VH Merger Sub I, Inc., VH Merger Sub II, LLC, Virex Health, Inc. and Fortis... (Filed With SEC on January 19, 2022)
Amended and Restated Sales Agreement, dated as of December 3, 2021, by and among Sorrento Therapeutics, Inc., Cantor Fitzgerald & Co., B. Riley Securities, Inc., H.C. Wainwright &... (Filed With SEC on December 3, 2021)
Loan Agreement, dated January 6, 2018, by and between Zhejiang ACEA Pharmaceutical Co., Ltd. and ACEA Bio (Hangzhou) Co., Ltd. (translated into English from its original text in... (Filed With SEC on June 4, 2021)
Contract, dated August 15, 2018, by and between Hangzhou ACEA Pharmaceutical Research Co., Ltd. and ACEA Bio (Hangzhou) Co., Ltd. (translated into English from its original text... (Filed With SEC on June 4, 2021)
Earn-Out Agreement, dated June 1, 2021, by and between Sorrento Therapeutics, Inc. and Fortis Advisors LLC (Filed With SEC on June 4, 2021)
Sorrento Therapeutics, Inc. Stock Appreciation Rights Award Agreement (Filed With SEC on May 5, 2021)
Sorrento Therapeutics, Inc. 2021 Cash-Settled Stock Appreciation Rights Plan (Filed With SEC on May 5, 2021)
Amendment to Binding Term Sheet, dated as of April 20, 2021, by and between Sorrento Therapeutics, Inc. and ANP Technologies, Inc (Filed With SEC on May 5, 2021)
Binding Term Sheet, dated as of February 24, 2021, by and between Sorrento Therapeutics, Inc. and ANP Technologies, Inc (Filed With SEC on May 5, 2021)
Agreement and Plan of Merger, dated April 2, 2021, by and among Sorrento Therapeutics, Inc., AT Merger Sub, Inc., ACEA Therapeutics, Inc. and Fortis Advisors LLC, as... (Filed With SEC on April 5, 2021)
Binding Term Sheet, dated as of October 14, 2020, by and between Sorrento Therapeutics, Inc. and ACEA Therapeutics, Inc (Filed With SEC on February 19, 2021)
License Agreement, dated as of October 12, 2020, by and between Sorrento Therapeutics, Inc. and Personalized Stem Cells (Filed With SEC on February 19, 2021)
Description of Securities of Sorrento Therapeutics, Inc (Filed With SEC on February 19, 2021)
Consent Under and Amendment No. 3 to Indenture and Letter of Credit, dated December 14, 2020, by and among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc., U.S. Bank... (Filed With SEC on December 15, 2020)
Amendment No. 1 to Sales Agreement, dated as of December 4, 2020, by and between Sorrento Therapeutics, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on December 4, 2020)
Patent and Know-How License Agreement, dated as of September 8, 2020, by and between Sorrento Therapeutics, Inc. and Mayo Foundation for Medical Education and Research (Filed With SEC on November 9, 2020)
Change of Control Severance Agreement, dated as of November 5, 2020, by and between Sorrento Therapeutics, Inc. and Najjam Ashgar (Filed With SEC on November 9, 2020)
Exclusive License Agreement, dated as of July 23, 2020, by and between Sorrento Therapeutics, Inc. and The Trustees of Columbia University in the City of New York (Filed With SEC on November 9, 2020)
License Agreement, dated as of July 13, 2020, by and between Sorrento Therapeutics, Inc. and ACEA Therapeutics, Inc (Filed With SEC on November 9, 2020)
Performance Stock Option Award Agreement, dated as of August 7, 2020, by and between Sorrento Therapeutics, Inc. and Henry Ji, Ph.D (Filed With SEC on October 20, 2020)
Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan (Filed With SEC on October 20, 2020)
Sorrento Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on October 20, 2020)
First Amendment to Exchange and Registration Rights Agreement, dated September 28, 2020, by and between Sorrento Therapeutics, Inc. and Fortis Advisors LLC in its capacity as the... (Filed With SEC on October 2, 2020)
Agreement and Plan of Merger, dated August 20, 2020, by and among Sorrento Therapeutics, Inc., SP Merger Sub, Inc., SmartPharm Therapeutics, Inc. and John C. Thomas, Jr., as... (Filed With SEC on August 20, 2020)
Outside Director Compensation Policy (Filed With SEC on August 4, 2020)
Binding Term Sheet, dated as of March 31, 2020, by and between Sorrento Therapeutics, Inc., and Nanjing Hongjing Enterprise Management Consulting Co., Ltd (Filed With SEC on May 11, 2020)
Omnibus Amendment No. 2 to Indenture and Letter of Credit, dated as of March 30, 2020, by and among Scilex Pharmaceuticals, Inc., Sorrento Therapeutics, Inc., U.S. Bank National... (Filed With SEC on May 11, 2020)
Common Stock Purchase Agreement, dated as of April 27, 2020, by and between Sorrento Therapeutics, Inc. and Arnaki Ltd (Filed With SEC on April 27, 2020)
Sales Agreement, dated as of April 27, 2020, by and between Sorrento Therapeutics, Inc. and A.G.P/Alliance Global Partners (Filed With SEC on April 27, 2020)
Description of Securities of Sorrento Therapeutics, Inc (Filed With SEC on March 3, 2020)
Registration Rights Agreement, dated as of February 10, 2020, by and between Sorrento Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 11, 2020)
Common Stock Purchase Agreement, dated as of February 10, 2020, by and between Sorrento Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 11, 2020)
Form of Warrant, dated December 6, 2019, issued by Sorrento Therapeutics, Inc (Filed With SEC on December 9, 2019)
Amendment No. 2 to the Registration Rights Agreement, dated as of December 6, 2019, by and among Sorrento Therapeutics, Inc. and the persons party thereto (Filed With SEC on December 9, 2019)
Note Conversion Agreement, dated as of November 8, 2019, by and among Sorrento Therapeutics, Inc. and the holders of convertible notes issued by Sorrento Therapeutics, Inc. as is... (Filed With SEC on November 12, 2019)
Amendment No. 1 to Agreement and Plan of Merger, dated as of August 7, 2019, by and between Scilex Holding Company and Fortis Advisors LLC, solely as the Equityholders... (Filed With SEC on November 12, 2019)
Form of Securities Purchase Agreement, dated October 7, 2019, by and between the Company and the purchasers party thereto (Filed With SEC on October 8, 2019)
Omnibus Amendment No. 1 to Indenture and Letter of Credit, dated as of October 1, 2019, by and among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc., U.S. Bank National... (Filed With SEC on October 1, 2019)
Equity Distribution Agreement, dated as of October 1, 2019, by and between Sorrento Therapeutics, Inc. and JMP Securities LLC (Filed With SEC on October 1, 2019)
Sorrento Therapeutics, Inc. 2019 Stock Incentive Plan (Filed With SEC on September 23, 2019)
Form of Series C Warrant (Filed With SEC on June 28, 2019)
Form of Series B Warrant (Filed With SEC on June 28, 2019)
Form of Series A Warrant (Filed With SEC on June 28, 2019)
Underwriting Agreement, dated as of June 28, 2019, by and between Sorrento Therapeutics, Inc. and JMP Securities LLC, as representative of the underwriters named therein (Filed With SEC on June 28, 2019)
Form of Warrant, dated May 3, 2019, issued by Sorrento Therapeutics, Inc (Filed With SEC on May 3, 2019)
Amendment No. 1 to Term Loan Agreement, dated as of May 3, 2019, by and among Sorrento Therapeutics, Inc., certain subsidiaries of Sorrento Therapeutics, Inc., as guarantors,... (Filed With SEC on May 3, 2019)
Amendment No. 1 to the Registration Rights Agreement, dated as of May 3, 2019, by and among Sorrento Therapeutics, Inc. and the persons party thereto (Filed With SEC on May 3, 2019)
Exchange and Registration Rights Agreement, dated as of March 18, 2019, by and among Sorrento Therapeutics, Inc. and the stockholders and stock option holders of Semnur... (Filed With SEC on March 22, 2019)
Agreement and Plan of Merger, dated as of March 18, 2019, by and among Sorrento Therapeutics, Inc., Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc.... (Filed With SEC on March 22, 2019)
First Amendment to Office Lease, dated October 19, 2018, between Sorrento Therapeutics, Inc. and HCP Life Science REIT, Inc (Filed With SEC on March 15, 2019)